Loading clinical trials...
Loading clinical trials...
Real-world Utilization Patterns of Aflibercept 8 mg in Japan: a Retrospective Descriptive Study Using the Claims Database
Conditions
Interventions
Aflibercept (Eylea, BAY86-5321)
Locations
1
Japan
Bayer
Osaka, Japan
Start Date
April 14, 2025
Primary Completion Date
March 31, 2026
Completion Date
July 30, 2027
Last Updated
March 10, 2026
NCT07308639
NCT07449936
NCT07449923
NCT07228559
NCT06075147
NCT04514653
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions